Chemical Industries Far East (C05) H2 2026 earnings summary

Executive summary

• FY2026 revenue was $60.634m and net loss narrowed to $0.919m from $21.457m, helped by the absence of the prior-year $10.1m Singapore plant impairment and lower costs.

• Operations faced weak demand, lower chemical selling prices, higher energy and logistics costs, and customer closures; management is pursuing cost efficiencies, new contracts and regional exports.

Financial highlights

• Revenue fell to $60.634m from $65.374m; gross profit rose to $8.488m from $3.837m.

• Loss before tax was $0.926m versus $22.102m; net loss was $0.919m versus $21.457m, with a $7,000 tax credit versus $645,000.

• Other expenses were $0.534m versus $17.466m; prior-year charges included a $10.1m PPE impairment and $6.222m onerous-contract provision increase.

• Net cash from operations was $3.3m versus $9.132m; year-end cash and cash equivalents were $20.086m versus $23.470m.

• Trade payables fell ~30% during the year; reported balance was $7.477m versus $10.957m.

Outlook and guidance

• Workforce right-sizing, started in FY2026, is targeted for completion by mid-FY2027 to streamline costs while maintaining operational continuity and productivity.

• Priorities include supply-chain and pricing reviews, operational efficiency, business continuity and resilience, and capturing growth opportunities as they arise.

• Proposed FY2026 final dividend is 0.5 cents per share, subject to shareholder approval at the AGM on 29 July 2026.